Spotlight: Advance Biotech Grant Program

Unlock your molecule’s potential. Apply to the US and Canada Advance Biotech Grant Program Your promising molecule requires resources and support to realize it’s potential. Our Advance Biotech Grant Program, 6th edition, is open to biotech start-up companies in US and Canada to help you accelerate to clinic faster. Apply now for a chance to win [...]

February 1st, 2019|

Spotlight: Biotech Companies in the “Big 3” Regions Rake in the Cash

  BioWeekSF will soon be here again — January 5-10, 2019 — the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation, the week’s premium online guide,, is showcasing a series of reports and other resources focusing on financing and dealmaking. This feature is from DealForma, the biopharma database providing you [...]

November 13th, 2018|

Spotlight: What Small and Emerging Companies Need When Entering Into Dealmaking Discussions

BioWeekSF will soon be here again -- January 6-11, 2019 -- the week of the J.P. Morgan Healthcare Conference and 20 other events and forums. In preparation,  the week's premium online guide,, is sponsoring a series of viewpoints and more from leaders and professionals involved in life sciences/healthcare dealmaking. As Chair of Foley Hoag's Licensing & [...]

October 14th, 2018|

Gilead Takes ‘Low Road’

Full feature More coverage: TheStreet: Gilead Sciences Bucks Tradition, Takes 'Low Road' on New Hepatitis C Drug Price More FierceBiotech: New Gilead hep C combo Epclusa gains FDA approval More STAT: FDA approves a Gilead pill that is first to treat all forms of hepatitis C More

June 29th, 2016|

KaloBios Reinvents Itself and How to Price Drugs

From The Bio Report/Daniel Levine: "KaloBios, a biotech best known for a series of disastrous events including failed clinical trials, a bankruptcy filing, lawsuits, and the arrest of its CEO, is being reborn. In the process, it may provide a valuable contribution to the ongoing discussion over drug pricing. In April, the development-stage company unveiled [...]

June 23rd, 2016|

Sean Parker to Fund Groundbreaking CRISPR Trial

UPDATE: A federal ethics and biosafety panel has approved the trial - coverage: Nature: First CRISPR clinical trial gets green light from US panel STAT: Federal panel approves first use of CRISPR in humans PREVIOUS: Internet billionaire Sean Parker is funding the first proposed test of CRISPR gene-editing technology in human beings. It would mark the first clinical trial involving CRISPR. Excerpts [...]

June 21st, 2016|

Cerus Wins Up-to-$180.5M BARDA Contract

Excerpt of coverage from GEN: "Under the BARDA contract, Cerus will receive initial funding of up to $30,750,939 to support activities related to a clinical trial to assess the safety and efficacy of Intercept RBCs compared to conventional RBCs in Puerto Rico, which has been impacted by the Zika virus epidemic. This funding also will [...]

June 20th, 2016|

Merck to Acquire Afferent Pharmaceuticals

From Merck press release: "Merck (NYSE:MRK), known as MSD outside the United States and Canada, and Afferent Pharmaceuticals announced today that the two companies have signed a definitive agreement under which Merck will acquire this privately held pharmaceutical company. Afferent Pharmaceuticals is a leader in the development of therapeutic candidates targeting the P2X3 receptor for [...]

June 10th, 2016|

Coverage of StemCells, Inc. Ceasing Operations

Coverage of StemCells, Inc. ceasing operations: Xconomy: "StemCells (NASDAQ: STEM) has decided to close up shop after its most advanced therapy didn’t do enough in a Phase 2 trial to improve people with spinal cord injuries. The one-time stem cell pioneer will wind down operations with $5.5 million in the bank, as of May 31, [...]

May 31st, 2016|

Pfizer to Buy Anacor in $5.2 Billion Deal

More from CNBC: Anacor shares soar 57% on $5.2B Pfizer acquisition "Shares of Anacor Pharmaceuticals spiked more than 57 percent Monday after it agreed to be bought by pharma giant Pfizer. Pfizer is buying Anacor in a $5.2 billion deal to add an eczema gel to its portfolio, just a month after the U.S. drug major [...]

May 17th, 2016|